Subba Rao A V, Swapna Konderu, Shaik Siddiq Pasha, Lakshma Nayak V, Srinivasa Reddy T, Sunkari Satish, Shaik Thokhir Basha, Bagul Chandrakant, Kamal Ahmed
Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India.
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad 500 037, India.
Bioorg Med Chem. 2017 Feb 1;25(3):977-999. doi: 10.1016/j.bmc.2016.12.010. Epub 2016 Dec 9.
A series of colchicine site binding tubulin inhibitors were synthesized by the modification of the combretastatin pharmacophore. The ring B was replaced by the pharmacologically relevant benzothiazole scaffolds, and the cis configuration of the olefinic bond was restricted by the incorporation of a triazole and tetrazole rings which is envisaged by the structural resemblance to a tubulin inhibitor like combretastatin (CA-4). These compounds were evaluated for their antiproliferative activity on selected cancer cell lines and an insight in the structure activity relationship was developed. The most potent compounds (9a and 9b) demonstrated an antiproliferative effect comparable to that of CA-4. Mitotic cell cycle arrest in G2/M phase revealed the disruption of microtubule dynamics that was confirmed by tubulin polymerization assays and immunocytochemistry studies at the cellular level. Western blot analysis revealed that these compounds accumulate more tubulin in the soluble fraction. The colchicine competitive binding assay and the molecular docking studies suggested that the binding of these mimics at the colchicine site of the tubulin is similar to that of CA-4. Moreover, the triggering of apoptotic cell death after mitotic arrest was investigated by studying their effect by Hoechst staining, Annexin-V-FITC assay, mitochondrial membrane potential, ROS generation and caspase-3 activation.
通过对康普他汀药效团进行修饰,合成了一系列秋水仙碱位点结合微管蛋白抑制剂。用具有药理活性的苯并噻唑支架取代B环,并通过引入三唑和四唑环来限制烯烃键的顺式构型,这是通过与像康普他汀(CA-4)这样的微管蛋白抑制剂的结构相似性设想的。对这些化合物在选定癌细胞系上的抗增殖活性进行了评估,并对构效关系有了深入了解。最有效的化合物(9a和9b)表现出与CA-4相当的抗增殖作用。有丝分裂细胞周期在G2/M期停滞,揭示了微管动力学的破坏,这在细胞水平上通过微管蛋白聚合测定和免疫细胞化学研究得到证实。蛋白质印迹分析表明,这些化合物在可溶性部分积累了更多的微管蛋白。秋水仙碱竞争性结合试验和分子对接研究表明,这些模拟物在微管蛋白秋水仙碱位点的结合与CA-4相似。此外,通过Hoechst染色、膜联蛋白-V-FITC测定、线粒体膜电位、活性氧生成和半胱天冬酶-3激活研究它们的作用,对有丝分裂停滞后凋亡细胞死亡的触发进行了研究。